bioboostresearch.com

The Nervous System

Labs Explore BioBoost Labs
Body & Peptide Science · System 03

The Nervous System

How the brain’s messengers, growth factors, and stress circuits work — and what the research literature actually documents about the peptides studied alongside them.

5 compounds studied13 primary sourcesResearch use only
Anatomical bio-scan of the The Nervous System
01

The system at a glance

The nervous system is a network of roughly 86 billion neurons that communicate through electrical impulses and chemical signals, coordinated by supporting glial cells. Beyond moment-to-moment signaling, the brain constantly remodels itself: synapses strengthen or weaken, and the survival and growth of neurons depend on a family of proteins called neurotrophins. Overlaid on this are slower regulatory systems that govern arousal, stress reactivity, mood, and the daily sleep-wake cycle. Much of the peptide research below targets these regulatory layers rather than fast synaptic transmission.

02

How it signals

Neurons talk using neurotransmitters such as glutamate (the brain’s main excitatory signal) and GABA (its main inhibitory brake), acting on receptors like the GABA-A and NMDA receptors. A separate class of longer-acting messengers — neuropeptides and neuromodulators — tune the gain of these circuits rather than carrying the primary message. Growth factors including brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) support plasticity and neuronal survival by binding receptors such as TrkB. The compounds surveyed here are studied for how they interact with these modulatory and neurotrophic pathways, largely in cell and animal models.

03

Research peptides studied in this system

Each card summarizes the documented mechanism, what was actually studied and in what model, and how strong the evidence is. These are descriptions of laboratory research — not recommendations, and not evidence of benefit in humans. According to research indexed in PubMed:

SemaxACTH(4-10) analogue; Met-Glu-His-Phe-Pro-Gly-ProEmerging / mixed
Documented mechanism
A synthetic heptapeptide derived from the 4-10 fragment of adrenocorticotropic hormone (ACTH). In rodent studies it has been reported to bind specific sites in the basal forebrain and to raise BDNF and activate BDNF/TrkB signaling in the hippocampus, with region-specific changes in NGF (increased in the hippocampus, decreased in the frontal cortex) — a pathway tied to synaptic plasticity. Effects on neurotrophin gene expression appear rapid and region-specific rather than uniform across the brain. 123
What was actually studied
Preclinical: cultured cells and Wistar rats, using intranasal application, real-time PCR of neurotrophin genes, and behavioral learning tasks. Mechanistic work is concentrated in Russian research groups.
Evidence tier
Documented mechanisms are largely from cell and rodent models; human cognitive data are more limited and not established to Western regulatory standards. RUO — mechanism only, not a treatment claim.
SelankTuftsin analogue; Thr-Lys-Pro-Arg-Pro-Gly-ProEmerging / mixed
Documented mechanism
A synthetic heptapeptide based on the immunopeptide tuftsin. Radioligand studies describe it acting as a positive allosteric modulator of GABA binding — a profile investigated as a possible basis for reported anti-anxiety (anxiolytic) activity. It has additionally been linked to changes in enkephalin metabolism. 456
What was actually studied
Preclinical: rat and mouse models (elevated-plus-maze behavior, receptor-binding assays). One Russian randomized comparison in generalized anxiety disorder and neurasthenia reported anxiolytic effects alongside biomarker changes.
Evidence tier
Independent pharmacology reviews note Selank is poorly studied outside a small literature and flag that GABAergic agents sold as supplements carry dependence and withdrawal considerations. Not an approved anxiety treatment in the US. RUO.
DSIPDelta sleep-inducing peptidePreclinical / early
Documented mechanism
A nonapeptide first isolated from cerebral blood associated with slow-wave (delta) sleep. Rather than acting as a classic sedative, the literature frames it as a neuromodulator implicated in stress adaptation: in rat models it has been reported to improve the efficiency of mitochondrial oxidative phosphorylation and to influence free-radical oxidation markers under experimental hypoxia and restraint stress. 78
What was actually studied
Preclinical: isolated rat brain mitochondria, liver homogenates, and stress models (hypoxia, physical restraint). Its precise receptor target and role in normal human sleep architecture remain unresolved.
Evidence tier
An older, sparse, and inconsistent literature; effects varied by dose and disappeared at higher amounts in some studies. Not demonstrated as a reliable human sleep agent. RUO — mechanism only.
PinealonGlu-Asp-Arg (short peptide bioregulator)Preclinical / early
Documented mechanism
A synthetic tripeptide from the ‘peptide bioregulator’ line associated with pineal/gerontology research. In animal models it is described as increasing neuronal resistance to hypoxic and oxidative stress — attributed less to direct radical scavenging and more to stimulation of the cell’s own antioxidant enzyme systems and possible limitation of NMDA-related excitotoxicity. 910
What was actually studied
Preclinical: rat models of hypobaric and prenatal hypoxia, oxidative-stress assays. Small, uncontrolled observational reports in older adults exist but are methodologically weak.
Evidence tier
Evidence is early, mostly from a single research tradition, and mechanisms are inferred rather than firmly mapped. No established human efficacy. RUO.
OxytocinEndogenous neurohypophyseal nonapeptideEstablished in parts
Documented mechanism
A naturally occurring hormone made in the hypothalamus (paraventricular and supraoptic nuclei) that acts both peripherally and as a central neuromodulator via oxytocin receptors. In the brain it can shift the balance of neurotransmitter release — for example enhancing glutamate release in the ventral hippocampus in one rat model — and modulate the hypothalamic-pituitary-adrenal (HPA) stress axis and amygdala-related circuits tied to anxiety and social behavior. 111213
What was actually studied
Extensively characterized as an endogenous signaling molecule; central roles studied in rodents and in human experiments using intranasal administration. Clinical trials have explored it in conditions such as autism and schizophrenia.
Evidence tier
The endogenous biology is well established; how much intranasally applied oxytocin reaches central receptors, and whether behavioral effects are specific or general, remains genuinely debated. RUO — this describes documented biology, not a treatment recommendation.
04

What we don’t know — and the risks

Honest limits matter as much as the mechanisms. For this system specifically:

  • Most mechanistic evidence for Semax, Selank, DSIP, and Pinealon comes from cell and rodent models and from a relatively narrow, largely Russian research literature — animal findings do not reliably predict human effects.
  • GABAergic compounds such as Selank act on the same receptor system as sedatives; independent pharmacology reviews raise dependence, withdrawal, and quality-control concerns for peptides sold as dietary supplements.
  • None of these peptides is an FDA-approved treatment for anxiety, cognitive, or sleep conditions in the United States; described effects are mechanistic, not endorsements of use.
  • The nervous system is tightly regulated by feedback loops (stress axis, sleep-wake cycle); pushing on one node can produce non-linear or dose-inverted effects, as several studies here observed.
  • This page covers documented mechanisms only. It provides no dosing, timing, administration, or protocol information — those questions belong with a qualified physician.
  • For any compound above, an available receptor or biomarker mechanism is not proof of a clinical benefit; several targets (e.g., DSIP’s receptor, intranasal oxytocin’s central delivery) remain unresolved in the literature.
05

Responsible understanding

◆ This is education, not medical advice

This page is educational and describes what has been studied in laboratory and clinical research. It is not medical advice, and these materials are for research use only — not for human or veterinary use. Timing, administration, and whether anything is used at all are clinical decisions that belong with a licensed physician overseeing your care; we take no position on them. Science and regulation evolve; verify anything important against the primary sources below.

06

Sources

Based on articles retrieved from PubMed. Follow each link to the original paper.

  1. Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry. 2006;J Neurochem. 2006;97 Suppl 1:82-6. DOI
  2. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;Brain Res. 2006;1117(1):54-60. DOI
  3. Agapova TY, Agniullin YV, Shadrina MI, et al. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10. Neuroscience Letters. 2007;Neurosci Lett. 2007;417(2):201-5. DOI
  4. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters. 2018;Protein Pept Lett. 2018;25(10):914-923. DOI
  5. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PubMed
  6. Doyno CR, White CM. Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. Journal of Clinical Pharmacology. 2021;J Clin Pharmacol. 2021;61 Suppl 2:S114-S128. DOI
  7. Khvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II. Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia. Peptides. 2003;Peptides. 2003;24(2):307-11. DOI
  8. Bobyntsev II, Kryukov AA, Belykh AE, Dudka VT. Effect of Delta Sleep-Inducing Peptide on Functional State of Hepatocytes in Rats During Restraint Stress. Bulletin of Experimental Biology and Medicine. 2016;Bull Exp Biol Med. 2016;160(4):421-4. DOI
  9. Kozina LS. Investigation of antihypoxic properties of short peptides. Advances in Gerontology (Uspekhi Gerontologii). 2008;Adv Gerontol. 2008;21(1):61-7. PubMed
  10. Umnov RS, Lin’kova NS, Khavinson VKh. Neuroprotective effects of peptides bioregulators in people of various age. Advances in Gerontology (Uspekhi Gerontologii). 2013;Adv Gerontol. 2013;26(4):671-8. PubMed
  11. Churchland PS, Winkielman P. Modulating social behavior with oxytocin: how does it work? What does it mean? Hormones and Behavior. 2011;Horm Behav. 2012;61(3):392-9. DOI
  12. Mairesse J, Gatta E, Reynaert ML, et al. Activation of presynaptic oxytocin receptors enhances glutamate release in the ventral hippocampus of prenatally restraint stressed rats. Psychoneuroendocrinology. 2015;Psychoneuroendocrinology. 2015;62:36-46. DOI
  13. Tom NC, Assinder SJ. Oxytocin: recent developments. Biomolecular Concepts. 2010;Biomol Concepts. 2010;1(5-6):367-80. DOI
Body & Peptide Science · The Nervous System · Draft for review
Research-use-only educational content. Nothing here is medical, dosing, timing, or treatment advice.
For research use only — not for human consumption, and not for diagnosing, treating, curing, or preventing any disease or condition, or making any medical claim. BioBoost Research is an educational resource. Science and regulation are evolving, and the information here may be incomplete, become outdated, or contain errors. Nothing here is medical, legal, or dosing advice — always verify against primary sources and consult a qualified professional. All information reflects facts as best known to BioBoost Research. Full disclaimer →

On clinical data and dosing: Any clinical trials, data, or dosing figures referenced anywhere on this site were conducted in controlled settings under qualified professional and physician oversight, and are shown for informational and educational purposes only — never as guidance. BioBoost Research makes no claim that the same outcome or safety profile would apply to any compound, person, or context. Research and educational use only · 21+.

Read the full Disclaimer →